Therapeutics News

Glaukos announced that Epioxa, its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, demonstrated statistically significant improvement from baseline vs. placebo in maximum corneal curvature at 12 months.

Filling an opioid prescription after ophthalmic surgery was associated with higher rates of hospitalization, overdose, abuse or dependency, and mortality, according to a study published in Ophthalmology.

Aldeyra Therapeutics has resubmitted a new drug application for topical reproxalap for the treatment of signs and symptoms of dry eye disease, the company announced in a press release.

Clobetasol propionate ophthalmic suspension 0.05% for postoperative inflammation and pain after ocular surgery is now commercially available in the U.S., according to a press release from Eyenovia.

LAS VEGAS — The pattern of fluorescein staining indicates the tear film layer affected by dry eye and, thus, dictates the treatment choice, Milton M. Hom, OD, FAAO, said at Vision Expo West.

After receiving a warning letter from the FDA on Aug. 16 citing “significant violations” related to two Regener-Eyes ophthalmic products, the company has implemented several improvements to address the concerns.

In this Healio video, Jacquie M. Bowen, OD, president-elect of the American Optometric Association, discusses the AOA’s recent consumer alert about over-the-counter color-changing eye drops.

AiViva Biopharma announced that it has completed enrollment and dosing of the last patient in a phase 1 clinical trial of AIV007 for wet age-related macular degeneration and diabetic macular edema.

LENZ Therapeutics has submitted a new drug application to the FDA for LNZ100, a preservative-free, once-daily aceclidine-based ophthalmic solution designed to treat presbyopia, the company announced in a press release.